Login to Your Account

Curis/Genentech's Vismodegib Aims for Smooth Approval Path

By Trista Morrison

Tuesday, September 13, 2011
Curis Inc. could soon collect an $8 million milestone payment from partner Genentech Inc., assuming the FDA accepts the newly filed new drug application (NDA) for vismodegib (RG3616/GDC-0449) in advanced, inoperable basal cell carcinoma (BCC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription